Cerevel Therapeutics Holdings, Inc. Stock
Equities
CERE
US15678U1280
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.24 USD | +0.43% | -0.05% | -0.38% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.7B |
---|---|---|---|---|---|
Net income 2024 * | -593M | Net income 2025 * | -559M | EV / Sales 2024 * | - |
Net cash position 2024 * | 619M | Net cash position 2025 * | 690M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-13
x | P/E ratio 2025 * |
-14.7
x | Employees | 355 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.44% |
Latest transcript on Cerevel Therapeutics Holdings, Inc.
1 day | +0.43% | ||
1 week | -0.05% | ||
Current month | -1.10% | ||
1 month | +0.93% | ||
3 months | -2.38% | ||
6 months | +65.91% | ||
Current year | -0.38% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 23-06-11 |
Director of Finance/CFO | 42 | 23-05-14 | |
N. Coles
CHM | Chairman | 63 | 18-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-05-31 | |
Douglas Giordano
BRD | Director/Board Member | 61 | 18-08-31 |
Ruth McKernan
BRD | Director/Board Member | 66 | 20-12-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 2 M€ | -.--% | ||
0.07% | 1,487 M€ | +7.21% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 42.24 | +0.43% | 726,778 |
24-05-13 | 42.06 | -0.31% | 652,651 |
24-05-10 | 42.19 | -0.26% | 474,428 |
24-05-09 | 42.3 | +0.57% | 1,295,038 |
24-05-08 | 42.06 | -0.47% | 1,120,947 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.38% | 7.66B | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- CERE Stock